Designing Prodrugs and Bioprecursors

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 561-585

  Wermuth, Camille G ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TARGETED DRUG DELIVERY;

DRUG SUBSTANCES; METABOLIZATION; PARENT COMPOUNDS; PARENT MOLECULES; PHARMACOKINETIC PARAMETERS; PHYSICOCHEMICAL PROPERTY; PROTECTIVE GROUP; STATE OF THE ART;

CONTROLLED DRUG DELIVERY;

EID: 84942868247     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50037-4     Document Type: Chapter

References (163)

1. 2-receptor Histamine Antagonists. Medicinal Chemistry. The Role of Organic Chemistry in Drug Research 1993, 228-255. Academic Press, New York. C.R. Ganellin, S.M. Roberts (Eds.).
2. A antagonists. Trends Pharmacol. Sci. 1986, 7:421-424.
3. A receptor antagonists. J. Med. Chem. 1992, 35:1969-1977.
4. Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-Co A reductase. J. Med. Chem. 1985, 28:401-405.
5. Lee T.J. Synthesis, SARs and therapeutic potential of HMG-Co A reductase inhibitors. Trends Pharmacol. Sci. 1987, 8:442-446.
6. Chang R.S.L., Lotti V.Y. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide CCK antagonist. Proc. Natl Acad. Sci. USA 1986, 83:4923-4926.
7. Wani M.C., Taylor H.L., Wall M.E., et al. Plant antitumor agents. IV. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Amer. Chem. Soc. 1971, 93:2325-2327.
8. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-669.
9. Ishida M., Miyazaki K., Kumagai K., Rikimaru M. Neocarzinostatine, an antitumor antibiotic of high molecular weight isolation, physical properties and biological activities. J. Antibiot. 1965, 18:68.
10. Gully D., Roger P., Wermuth C.G. Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containiing them 1999, US Patent 5880135.
11. Gilligan P.J., Robertson D.W., Zaczek R. Corticotropin releasing factor modulators: progress and opportunities for new therapeutic agents. J.Med.Chem. 2000, 43:1641-1658.
12. Albert A. Chemical aspects of selective toxicity. Nature (London) 1958, 182:421-423.
13. Harper N.J. Drug latentiation. J. Med. Pharm. Chem. 1959, 1:467-500.
14. Wermuth C.G. Bioprécurseurs contre prodrogues. Drug Metabolism and Drug Design: Quo Vadis? 1983, 253-271. Sanofi-Clin-Midy, London.
15. Wermuth C.G. Designing prodrugs and bioprecursors. Drug Design: Fact or Fantasy? 1984, 47-72. Academic Press, Montpellier.
16. Sinkula A.A. Prodrugs, protective groups and the medicinal chemist. Medicinal Chemistry 1977, 125-133. Elsevier, London.
17. Stella V. Pro-drugs: an overview and definition. Pro-drugs as a Novel Drug Delivery System 1975, 1-115. American Chemical Society, Amsterdam.
18. Wermuth C.G. Les prodrogues, des médicaments plus sôrs et plus maniables. Bull. Soc. Pharm. Bordeaux 1980, 119:107-129.
19. Wermuth C.G. Modulation of natural substances in order to improve their pharmacokinetic properties. Natural Products as Medicinal Agents 1981, 185-216. Hippokrates Verlag, Washington DC.
20. Daehne W.V., Frederiksen E., Gundersen E., et al. Acyloxymethyl esters of ampicillin. J. Med. Chem. 1970, 13:607-612.
21. Bodin N.O., Ekström B., Forsgren U., et al. Bacampicilline: a new orally well-absorbed derivative of ampicillin. Antimicrob. Agents Chemother. 1975, 8:518-525.
22. Clayton J.P., Cole M., Elson S.W., et al. Preparation, hydrolysis, and oral absorption of lactonyl esters of penicillins. J. Med. Chem. 1976, 19:1385-1391.
23. Testa B., Jenner P. Drug Metabolism, Chemical and Biochemical Aspects 1976, Marcel Dekker, Stuttgart.
24. Shen T.I., Witzel B.E., Jones H., et al. Synthesis of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl) benzylidenyl]-indene-3-acetic acid. Fed. Proc. 1972, 31:577.
25. Hucker H.B., Stauffer S.C., White S.D., et al. Physiological disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl) benzylidenyl]-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab. Dispos. 1973, 1:721-736.
26. Duggan D.E., Hare L.E., Ditzler C.A., et al. The disposition of sulindac. Clin. Pharmacol. Ther. 1977, 21:326-335.
27. Duggan D.E., Hooke K.F., Noll R.M., et al. Comparative biodisposition of sulindac and metabolites in five species. Biochem. Pharmacol. 1978, 27:2311-2320.
28. Duggan D.E., Hooke K.F., Risley E.A., et al. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther. 1977, 201:8-13.
29. Drabek J., Neumann R. Proinsecticides. Progress in Pesticide Biochemistry and Toxicology 1985, 35-86. John Wiley & Sons, New York.
30. Higuchi T., Stella V. Pro-drugs as novel drug delivery systems. ACS Symposium Series 1975, American Chemical Society, Chichester. A.C. Society (Ed.).
31. Bundgaard H. Design and application of prodrugs. A Textbook of Drug Design and Development 1991, 113-191. Harwood Academic Publisher, Washington DC. 1st edn.
32. McClure D. The effect of a pro-drug of epinephrine (dipivaloyl-epinephrine) in glaucoma - general pharmacology, toxicology and clinical experience. Pro-Drugs as Novel Drug Delivery Systems 1975, 224-235. American Chemical Society, Chur.
33. Horn A.S. Pro-drugs of dopaminergic agonists. Chem. Ind. 1980, 441-444.
34. Westerink B.H.C., Dijkstra D., Feenstra M.G.P., et al. Dopaminergic prodrugs: brain concentration and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters. Eur. J. Pharmacol. 1980, 61:7-15.
35. Tullar B.F., Minatoya H., Lorenz R.R. Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects. J. Med. Chem. 1976, 19:834-838.
36. Lin T.S. Synthesis and in vitro antiviral activity of 3'-O-acyl derivatives of 5'-amino-2'-deoxy thymidine: potential prodrugs for topical application. J. Pharm. Sci. 1984, 73:1568-1571.
37. Harnden M.R., Jarvest R.L., Boyd M.R., et al. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J. Med. Chem. 1989, 32:1738-1743.
38. Jones L.A., Moorman A.R., Chamberlain S.D., et al. Di- and triester prodrugs of the Varicella-Zoster antiviral agent 6-methoxy-purine arabinoside. J. Med. Chem. 1992, 35:56-63.
39. Bodor N., Sloan K.B., Little R.J., et al. Soft drugs 4. 3-Spirothiazolidines of hydrocortisone and its derivatives. Int. J. Pharm. 1982, 10:307-321.
40. Collis A.J. Drug access and prodrugs. Medicinal Chemistry-The Role of Organic Chemistry in Drug Research 1993, 61-82. Academic Press, Washington DC. 2nd edn.
41. Anden N.E., Corrodi H., Dahlström A., Fuxe K., Högfelt T. Effects of tyrosine hydroxylase inhibition on the amine levels of central monoamine neurons. Life Sci. 1966, 5:561-568.
42. Anonymous Etilevodopa. Drugs of the Future 2001, 26:219-223.
43. Frey H.H., Popp C., Löscher W. Influence of inhibitors of the high affinity GABA uptake on seizure threshold in mice. Neuropharmacology 1979, 18:581-590.
44. Ulm E.H., Hichens M., Gomez H.J., et al. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br. J. Pharmacol. 1982, 14:357-362.
45. Swanson B.L., Vlasses P.H., Ferguson R.K., et al. Influence of food on the bioavailability of enalapril. J. Pharm. Sci. 1984, 73:1655-1657.
46. Zannad F. Trandolapril, how does it differ from other angiotensin converting enzyme inhibitors?. Drugs 1993, 46:172-183.
47. Tsybina N.M., Ostrovskaya R.U., Protopova T.V., et al. Synthesis and pharmacological activity of gamma-aminobutyric acid derivatives. Khim. Pharm. Zh. 1974, 17:10-13.
48. Ostrovskaya R.U., Parin V.V., Tsybina N.M. The comparative neurotropic potency of gamma-aminobutyric acid and its cetyl ester. Byul. Eksp. Biol. Med. 1972, 73:51-55.
49. Beardsley G.P., Rosowsky A. Effect of methotrexate γ-monohexadecyl ester (γ-MHxMTX) on nucleoside uptake by human leukemic cells. Proc. Am. Assoc. Cancer Res. 1980, 21:264. (71st Meeting).
50. Wermuth C.G., Gaignault J.-C., Marchandeau C. Designing prodrugs and bioprecursors I: carrier prodrugs. The Practice of Medicinal Chemistry 1996, 671-696. Academic Press, London.
51. Jones G. Lipoidal pro-drug analogues of various anti-inflammatory agents. Chem. Ind (London) 1980, 452-456.
52. Jansen A.B.A., Russel T.J. Some novel penicillin derivatives. J. Chem. Soc. 1965, 2127-2132.
53. Binderup E., Godtfredsen W.O., Roholt K. Orally active cephaloglycin esters. J. Antibiot. 1971, 24:767-773.
54. Saari W.S., Halczenko W., Cochran D.W., et al. 3-Hydroxy-α-methyltyrosine progenitors: synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methyl esters. J. Med. Chem. 1984, 27:713-717.
55. Falch E., Krogsgaard-Larsen P., Christensen A.V. Esters of isoguvacine as potential prodrugs. J. Med. Chem. 1981, 24:285-289.
56. Svahn C.M., Merenyi F., Karlson L. Tranexamic acid derivatives with enhanced absorption. J. Med. Chem. 1986, 29:448-453.
57. Torriani H. Talniflumate. Drugs Fut. 1979, 4:448-450.
58. Torriani H. Talmetacin. Drugs Fut. 1982, 7:823-824.
59. Alexander J., Fromtling R.A., Bland J.A., et al. (Acyloxy) alkyl carbamate prodrugs of norfloxacin. J. Med. Chem. 1991, 34:78-81.
60. Ahlmark M., Vepsaelaeinen J., Taipale H., et al. Bisphophonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate. J.Med.Chem. 1999, 42:1473-1476.
61. Aicher T.D., Bebernitz G.R., Bell P.A., et al. Hypoglycemic Prodrugs of 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid. J.Med.Chem. 1999, 42:153-163.
62. Young D.A., Ho R.S., Bell P.A., et al. Inhibition of hepatic glucose production by SDZ 51641. Diabetes 1990, 39:1408-1413.
63. Walsh D.A., Moran H.W., Shamblee D.A., et al. Anti-inflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid. J. Med. Chem. 1990, 33:2296-2304.
64. Galzinga L., Garbin L., Bianchi M., Marzotto A. Properties of two derivatives of γ-aminobutyric acid (GABA) capable of abolishing cardiazol- and bicuculline-induced convulsions in the rat. Arch. int. Pharmacodyn. 1978, 235:73-85.
65. Ahtee L., Halmekoski J., Heinonen H., Koskimies A. Comparison of the central nervous system actions of taurine and N-pivaloyltaurine. Br. J. Pharmacol 1979, 66. 480P.
66. Kaplan J.P., Raizon B., Desarmenien M., et al. New anticonvulsants: Schiff bases of γ-aminobutyric acid and γ-aminobutyramide. J. Med. Chem. 1980, 23:702-704.
67. Jensen N.P., Friedman J.J., Kropp H., Kahan F.M. Use of acetylacetone to prepare a prodrug of cycloserine. J. Med. Chem. 1980, 23:6-8.
68. Bodor N.S., Sloan K.B., Hussain A.A. Novel Transient Pro-drug Forms of L-DOPA 1975, US Patent 3 891 696 (24 June 1975; Inter'X Res. Corp.).
69. Koch H. Drugs Future 1981, 6:244-246. ST-1059.
70. Vicentini C.B., Guarneri M., Sarto G. Hypoglycemic compounds. Sulfonylurea derivatives containing amino acids and dipeptides. Farmaco, Ed Sci. 1983, 38:595-608.
71. Rubenstein S.M., Baichwal V., Beckmann H., et al. Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood-brain barrier. J. Med. Chem. 2001, 44:3599-3605.
72. Boehringer Dérivés de la L-(3,4-dihydroxy-phényl)-2-méthyl alanine et leur préparation 1976, Belgium Patent 839 362 (9 March 1976; Boehringer Mannheim GMBH).
73. Kingsbury W.D., Boehm J.C., Mehta R.J., Grappel S.F. Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine peptide conjugates. J. Med. Chem. 1983, 26:1725-1729.
74. Hu M., Subramanian P., Mosberg H.I., Amidon G.L. Use of the peptide carrier system to improve the intestinal absorption of l-α-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of l-α-methyldopa. Pharm. Res. 1989, 6:66-70.
75. Rahmathullah S.M., Hall J.E., Bender B.C., et al. Prodrugs for amidines: synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan. J.Med.Chem. 1994, 42:3994-4000.
76. Buur A., Bundgaard H., Falch E. Prodrugs of 5-fluorouracil. VII. Hydrolysis kinetics and physicochemical properties of N-ethoxy- and N-phenoxycarbonylmethyl derivatives of 5-fluorouracil. Acta Pharm. Suec. 1986, 23:205-216.
77. Larsen J.D., Bundgaard H. Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonyl-sulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharm. 1987, 37:87-95.
78. Bundgaard H., Buur A., Hansen K.T., et al. Prodrugs as drug delivery systems. 77. Phtalidyl derivatives as prodrug form for amides, sulfonamides, carbamates and other NH-acidic compounds. Int. J. Pharm. 1988, 45:47-57.
79. Hardcastle G.A., Johnson D.A., Panetta C.A., et al. The preparation and structure of hetacillin. J. Org. Chem. 1966, 31:897-899.
80. Design of prodrugs: bioreversible derivatives for various functional groups and chemical entities. Design of Prodrugs 1985, 1-92. Elsevier, London. H. Bundgaard (Ed.).
81. Anonymous Droxicam. Drugs Fut. 1986, 11:835-836.
82. Zeller P., Pletscher A., Gey K.F., et al. Amino acid and fatty acid hydrazides: chemistry and action on monoamine oxidase. Ann. N.Y. Acad. Sci. 1959, 80:555-567.
83. Knapp F.F.J., Goodman M.M., Callahan A.P., et al. New myocardial imaging agents: stabilization of radioiodine as a terminal vinyl iodide moiety on tellurium fatty acids. J. Med. Chem. 1983, 26:1293-1300.
84. Wess G., Kramer W., Schubert G., et al. Coupling of Drugs to Modified Bile Acids for Liver Specific Targeting. Abst. Pap. 205th Meet. Am. Chem. Soc. 1993, Pt. 1, MEDI 152.
85. Nagy A., Schally A.V. Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers. Drugs of the Future 2001, 26:261-270.
86. Biel J.H., Martin Y.C. Organic synthesis as a source of new drugs. Drug Discovery - Science and Development in a Changing Society 1971, 81-111. American Chemical Society, Amsterdam.
87. Whittaker J.R. Biosynthesis of a thiouracil pheomelanin in embryonic pigment cells exposed to thiouracil. J. Biol. Chem. 1971, 246:6217-6226.
88. Dencker L., Larsson B., Olander K., Ullberg S., Yokota M. False precursors of melanin as selective melanoma seekers. Br. J. Cancer 1979, 39:449-452.
89. Wätjen F., Buchardt O., Langvad E. Affinity therapeutics. 1. Selective incorporation of 2-thiouracil derivatives in murine melanomas. Cytostatic activity of 2-thiouracil arotinoids, 2-thiouracil retinoids, arotinoids and retinoids. J. Med. Chem. 1982, 25:956-960.
90. Ariëns E.J. Modulation of pharmacokinetics by molecular manipulation. Drug Design 1971, 1-127. Academic Press, Washington DC.
91. Ariëns E.J. Pharmacological basis of cancer therapy. Twenty-Seventh Annual Symposium on Fundamental Cancer Research 1975, The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston: The Williams and Wilkins Company, New York.
92. Hurwitx E., Kashi R., Burowsky D., et al. Site-directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM. Int. J. Cancer 1983, 31:745-748.
93. Magnan S.D.J., Shirota F.N., Nagasawa H.T. Drug latentiation by γ-glutamyl transpeptidase. J. Med. Chem. 1982, 25:1018-1021.
94. Wilk S., Mizoguchi H., Orlowski M. Gamma-glutamyl-DOPA: a kidney specific dopamine precursor. J. Pharmacol. Exp. Ther. 1978, 206:227-232.
95. Kyncl J.J., Minard F.N., Jones P.H. Peripheral dopamine receptors. Symposium on Peripheral Dopaminergic Receptors-Strasbourg 1979, 369-380. Pergamon Press, Baltimore.
96. Jones P.H., Kyncl J., Ours C.W., Somani P. Esters of γ-Glutamyl Amide of Dopamine 1977, US Patent 4 017 636 (12 April 1977; Abott Laboratories).
97. Orlowski M., Mizoguchi H., Wilk S. N-acyl-γ-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs. J. Pharmacol. Exp. Ther. 1979, 212:167-172.
98. Friend D.R., Chang G.W. Drug glycosides: potential prodrugs for colon-specific drug delivery. J. Med. Chem. 1985, 28:51-57.
99. Friend D.R., Chang G.W. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. Chem. 1984, 27:261-266.
100. Cook A.F., Holman M.J., Kramer M.J., Trown P.W. Florinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides. J. Med. Chem. 1979, 22:1330-1335.
101. Au J.L.-S., Walker J.S., Rustum Y. Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. J. Pharmacol. Exptl. Ther. 1983, 227:174-180.
102. de Groot F.M.H., van Berkom L.W.A., Scheeren H.W. Synthesis and biological evaluation of 2'-carbamate-linked and 3'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J.Med.Chem. 2000, 43:3093-3102.
103. Stella V.J., Charman W.N.A., Naringrekar V.H. Prodrugs, do they have advantages in clinical practice?. Drugs 1985, 29:455-473.
104. Sinkula A.A. Sustained drug action accomplished by the prodrug approach. Design of Prodrugs 1985, 157-176. Elsevier, Oxford. H. Bundgaard (Ed.).
105. Dusterberg B., Wendt H. Plasma levels of dehydroepian-drosterone and 17β-estradiol after intramuscular administration of Gynodian-Depot® in three women. Hormone Res. 1983, 17:84-89.
106. Falconi G., Galetti F., Celasco G., Gardi R. Oral long-lasting estrogenic activity of estradiol 3-benzoate 17-cyclooctenyl ether. Steroids 1972, 20:627-632.
107. 4-3-Keto steroidal ethers. Paradoxical dependency of their effectiveness on the administration route. J. Am. Chem. Soc. 1960, 82:746-748.
108. Cain B.F. The role of structure-activity studies in the design of antitumor agents. Cancer Chemother. Rep. 1975, 59:679-683.
109. Cain B.F. 2-Acyloxymethylbenzoic acids. Novel amine protective functions providing amides with the lability of esters. J. Org. Chem. 1976, 41:2029-2031.
110. Sakamoto F., Ikeda S., Tsukamoto G. Studies on Prodrugs. II. Preparation and characterization of (5-substituted 2-oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin. Chem. Pharm. Bull. 1984, 32:2241-2248.
111. Bundgaard H. Novel chemical approaches in prodrug design. Drugs Fut. 1991, 16:443-458.
112. Borgman R.J., Smith R.V., Keiser J.E. The acetylation of apomorphine. An improved method for the selective preparation of diacetylapomorphine utilizing trifluoroacetic acid/acetyl bromide. Synthesis 1975, 249-250.
113. Nicolaou K.C., Riemer C., Kerr M.A., et al. Design, synthesis and biological activity of protaxols. Nature (London) 1993, 364:464-466.
114. Nicolaou K.C., Guy R.K., Pitsinos E.N., Wrasidlo W. A water-soluble prodrug of Taxol with self-assembling properties. Angew. Chem. Internat. Ed. Engl. 1994, 33:1583-1586.
115. Norbeck D.W., Rosenbrook W., Kramer J.B., et al. A novel prodrug of an impermeant inhibitor of 3-deoxy-d-manno-2-octulosonate cytidylyl-transferase has antibacterial activity. J. Med. Chem. 1989, 32:625-629.
116. Bundgaard H., Falch E., Larsen C., Mikkelson T.J. Pilocarpine prodrugs I. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. J. Pharm. Sci. 1986, 75:36-44.
117. Bundgaard H., Falch E., Larsen C., et al. Pilocarpine prodrugs II. Synthesis, stability, bioconversion and physicochemical properties of sequentially labile pilocarpine acid diesters. J. Pharm. Sci. 1986, 75:775-783.
118. Amsberry K.L., Borchardt R.T. Amine prodrugs which utilize hydroxy-amide lactonization. I. A potential redox-sensitive amide prodrug. Pharm. Res. 1991, 8:323-330.
119. Amsberry K.L., Gerstenberger A.E., Borchardt R.T. Amine prodrugs which utilize hydroxy-amide lactonization. II. A potential esterase-sensitive prodrug. Pharm. Res. 1991, 8:455-461.
120. Bodor N.S. Novel approaches for the design of membrane transport properties of drugs. Design of Biopharmaceutical Properties through Prodrugs and Analogs 1977, 98-135. American Pharmaceutical Association, Amsterdam. E.B. Roche (Ed.).
121. Bodor N.S., Kaminski J.J., Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J. Med. Chem. 1980, 23:469-474.
122. Bodor N.S., Kaminski J.J. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J. Med. Chem. 1980, 232:566-569.
123. Bodor N.S., Woods R., Raper C., et al. Soft drugs. 3. A new class of anticholinergic agents. J. Med. Chem. 1980, 23:474-480.
124. Bodor N. Prodrugs versus soft drugs. Design of Prodrugs 1985, 333-354. Elsevier, Washington DC. H. Bundgaard (Ed.).
125. Pitman I.H. Pro-drugs of amides, imides, and amines. Medicinal Research Reviews 1981, 189-214. John Wiley & Sons, Amsterdam.
126. Carini D.J., Duncia J.V., Aldrich P.E., Chiu A.T., Johnson A.L., Piera M.E., Price W.A., Santella J.B., Wells G.J., Wexler R.R., et al. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylymethyl) imidazoles as potent, orally active antihypertensives. J.Med.Chem. 1991, 34:2525-2547.
127. Wong P.C., Price W.A., Chiu A.T., Duncia J.V., Corini D.J., Wexler R.R., Johnson A.L., Timmermans P.B. Nonpeptide angiotension II receptor antagonists. XI. Pharmacology of Exp 3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 1990, 255:211-217.
128. Baldessarini R.J., Neumeyer J.L., Campbell A., et al. An orally effective, long-acting dopaminergic prodrug: (-)-10,11-methylenedioxy-N-propylnorapomorphine. Eur. J. Pharmacol. 1982, 77:87-88.
129. Bodor N., Shek E., Higuchi T. Improved delivery through biological membranes. 1. Synthesis and properties of 1-methyl-1,6-dihydropyridine-2-carbaldoxime, a pro-drug of N-methyl-pyridinium-2-carbaldoxime chloride. J.Med.Chem. 1976, 19:102-107.
130. Shek E., Higuchi T., Bodor N. Improved delivery through biological membranes. 2. Distribution, excretion, and metabolism of N-methyl-1,6-dihydropyridine-2-carbaldoxime hydrochloride, a pro-drug of N-methylpyridinium-2-carbaldoxime chloride. J. Med. Chem. 1976, 19:108-112.
131. Shek E., Higuchi T. Improved delivery through biological membranes. 3. Delivery of improved delivery through biological membranes. 3. Delivery of N-methylpyridinium-2-carbaldoxime chloride through the blood-brain-barrier in its dihydropyridine prodrug form. J. Med. Chem. 1976, 19:113-117.
132. Krenitsky T.A., Hall W.W., de Miranda P., et al. Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc. Natl Acad. Sci. USA 1984, 31:3209-3213.
133. Whiteman P.D., Bye A., Fowle A.S.E., et al. Tolerance and pharmacokinetics of A515U, an acyclovir analogue in healthy volunteers. Eur. J. Clin. Pharmacol. 1984, 27:471-475.
134. Gershwin M.E., Goetzl E.J., Steinberg A.D. Cyclophosphamide: use in practice. Ann. Intern. Med. 1974, 80:531-540.
135. Silverman R.B. The Organic Chemistry of Drug Design and Drug Action 1992, 380. Academic Press, New York.
136. Zon G. Cyclophosphamide analogues. Progress in Medicinal Chemistry 1982, 205-246. Elsevier, San Diego. G.P. Ellis, G.B. West (Eds.).
137. Arnold H., Bourseaux F., Brock N. NeuartigeKrebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-phosphamidester. Naturwissenschaften 1958, 45:64-66.
138. Arnold H., Bourseaux F., Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B518-ASTA) in experimental tumours of the rat. Nature 1958, 181:931.
139. Arnold H. Ueber die Chemie neuer zytostatisch wirksamer N-Chloroaethyl-phosphorsäureesterdiamide. Proceedings of the Fifth International Congress on Chemotherapy 1967, 751-754. Verlag der Wiener Medizinischen Akademie, Amsterdam. K. Spitzy, H. Haschet (Eds.).
140. Kennedy K.A., Teicher B.A., Rockwell S., Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 1980, 29:1-8.
141. Davis P.J., Guenthner L.E. Sulindac oxidation/reduction by microbial cultures; microbial models for mammalian metabolism. Xenobiotica 1985, 15:845-857.
142. Kwon C.-H., Blanco D.R., Baturay N. p-(Methylsulfinyl)phenyl nitrogen mustard as a novel bioreductive prodrug selective against hypoxic tumours. J. Med. Chem. 1992, 35:2137-2139.
143. +)-ATPase within the parietal cell. Biochim. Biophys. Acta 1984, 778:549-558.
144. Lamers C.B.H.W., Lind T., Moberg S., et al. Omeprazole in Zollinger-Ellison syndrome. N. Engl. J. Med. 1984, 310:758-761.
145. +-activated oxidizing agent of sulfhydryl groups. J. Biol. Chem. 1985, 260:4591-4597.
146. Lindberg P., Nordberg P., Alminger T., et al. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem. 1986, 33:1327-1329.
147. Krausz F., Demarne H., Vaillant J., et al. Anti-inflammatoires non stéroidiques: Dérivés de l'acide phényl-4-butyrique et phényl-4, oxo-4, butyrique. Arzneim.-Forsch (Drug Res.) 1974, 24:1360-1364.
148. Gros P.M., Davi H.J., Chasseaud L.F., Hawkins D.R. Metabolic and pharmacokinetic study of bucloxic acid. Arzneim.-Forsch (Drug Res.) 1974, 24:1385-1390.
149. Kohler C., Tolman E., Wooding W., Ellenbogen L. A review of the effects of Fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneim.-Forsch (Drug Res.) 1980, 30:702-707.
150. Chicarelli F.S., Eisner H.J., Van Lear G.E. Disposition and metabolism of Fenbufen in several laboratory animals. Arzneim.-Forsch (Drug Res.) 1980, 30:707-715.
151. Martel R.R., Rochefort J.G., Klicius J., Dobson T.A. Anti-inflammatory properties of Furobufen. Can. J. Physiol. Pharmacol. 1974, 52:669-673.
152. Gilard J.W., Belanger P. Metabolic synthesis of arylacetic acid antiinflammatory drugs from arylhexenoic acids. 2. Indomethacin. J. Med. Chem. 1987, 30:2051-2058.
153. Williamson J.M., Meister A. Stimulation of hepatic glutathione formation by administration of l-2-oxothiazolidine-4-carboxylate, a 5-oxo-1-prolinase substrate. Proc. Natl Acad. Sci. USA 1981, 78:936-939.
154. Matsukawa T., Yuruki S., Oka Y. The synthesis of S-acylthiamine derivatives and their stability. Ann. NY Acad Sci. 1962, 98:430-444.
155. Thomson A.D., Frank O., Baker H., Leevy C.M. Thiamine propyl disulphide: absorption and utilization. Ann. Intern. Med. 1971, 74:529-534.
156. Bodor N., Farag H.H., Brewster M.E. Site-specific, sustained release of drugs to the brain. Science 1981, 214:1370-1372.
157. Cousse H., Casadio S., Mouzin G. L'hydroxy éthyl nicotinamide vecteur d'acides thérapeutiquement actifs. Trav. Soc. Pharm. Montpellier 1978, 38:71-76.
158. Casadio S., Cousse H., Mouzin G. Nouvelles formes modulées de médicaments utilisant les N-hydroxy alcoyl pyridine carboxamides comme vecteur 1978, French Patent No. 77 13478 (May 2, 1977; P. Fabre S. A.).
159. Vezin J.C., Mouzin G., Cousse H., Casadio S. Nicafenine, a new analgesic. Arzneimit.-Forsch. 1979, 29:1659-1661.
160. Gorrod J.W. Potential hazards of the pro-drug approach. Chem. Ind. 1980, 457-461.
161. Roberts J.C., Nagasawa H.T., Zera R.T., et al. Prodrugs of l-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(Polyacetoxyalkyl)thiazolidine-4(R)-carboxylic Acids. J. Med. Chem. 1987, 30:1891-1896.
162. Saari W.S., Freedman M.B., Hartman R.D., et al. Synthesis and antihypertensive activity of some ester progenitors of methyldopa. J. Med. Chem. 1978, 21:746-753.
163. Vickers S., Duncan C.A., White S.D., et al. Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat. Drug Metab. Dispos. 1978, 6:640-646.